BRPI0511088A - identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib - Google Patents
identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinibInfo
- Publication number
- BRPI0511088A BRPI0511088A BRPI0511088-2A BRPI0511088A BRPI0511088A BR PI0511088 A BRPI0511088 A BR PI0511088A BR PI0511088 A BRPI0511088 A BR PI0511088A BR PI0511088 A BRPI0511088 A BR PI0511088A
- Authority
- BR
- Brazil
- Prior art keywords
- sensitive
- characterization
- subset
- identification
- glioblastomas
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title abstract 2
- 238000012512 characterization method Methods 0.000 title abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002411 imatinib Drugs 0.000 title abstract 2
- 208000005017 glioblastoma Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 229940124090 Platelet-derived growth factor (PDGF) receptor antagonist Drugs 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0410883A GB0410883D0 (en) | 2004-05-14 | 2004-05-14 | Organic compounds |
| GB0425257A GB0425257D0 (en) | 2004-11-16 | 2004-11-16 | Organic compounds |
| PCT/EP2005/005269 WO2005113801A2 (en) | 2004-05-14 | 2005-05-13 | Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511088A true BRPI0511088A (pt) | 2007-12-26 |
Family
ID=35295424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511088-2A BRPI0511088A (pt) | 2004-05-14 | 2005-05-13 | identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080199855A1 (enExample) |
| EP (1) | EP1756306A2 (enExample) |
| JP (1) | JP2007536920A (enExample) |
| AU (1) | AU2005245572B9 (enExample) |
| BR (1) | BRPI0511088A (enExample) |
| CA (1) | CA2564654A1 (enExample) |
| MX (1) | MXPA06013079A (enExample) |
| RU (1) | RU2006144122A (enExample) |
| WO (1) | WO2005113801A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2132336A1 (en) * | 2007-03-02 | 2009-12-16 | Board of Regents, The University of Texas System | Multigene assay to predict outcome in an individual with glioblastoma |
| JP6159085B2 (ja) * | 2009-08-25 | 2017-07-05 | バーグ エルエルシー | エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法 |
| KR20140044341A (ko) * | 2011-06-02 | 2014-04-14 | 알막 다이아그노스틱스 리미티드 | 암에 대한 분자적 진단 검사 |
| WO2014087156A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2829154B1 (fr) * | 2001-09-05 | 2003-10-17 | Assist Publ Hopitaux De Paris | Nouveau procede de detection d'une mutation en phase de lecture dans une sequence codante et appareil pour sa mise en oeuvre |
| EP1497463A1 (en) * | 2002-04-17 | 2005-01-19 | Novartis AG | Methods to predict patient responsiveness to tyrosine kinase inhibitors |
| JP4035600B2 (ja) * | 2002-05-22 | 2008-01-23 | 国立大学法人 東京大学 | イマチニブに対する感受性の判定方法 |
-
2005
- 2005-05-13 BR BRPI0511088-2A patent/BRPI0511088A/pt not_active IP Right Cessation
- 2005-05-13 JP JP2007512116A patent/JP2007536920A/ja active Pending
- 2005-05-13 US US11/568,781 patent/US20080199855A1/en not_active Abandoned
- 2005-05-13 EP EP05741985A patent/EP1756306A2/en not_active Withdrawn
- 2005-05-13 WO PCT/EP2005/005269 patent/WO2005113801A2/en not_active Ceased
- 2005-05-13 CA CA002564654A patent/CA2564654A1/en not_active Abandoned
- 2005-05-13 AU AU2005245572A patent/AU2005245572B9/en not_active Expired - Fee Related
- 2005-05-13 MX MXPA06013079A patent/MXPA06013079A/es not_active Application Discontinuation
- 2005-05-13 RU RU2006144122/13A patent/RU2006144122A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005113801A2 (en) | 2005-12-01 |
| RU2006144122A (ru) | 2008-06-20 |
| WO2005113801A3 (en) | 2006-02-23 |
| AU2005245572A1 (en) | 2005-12-01 |
| AU2005245572B2 (en) | 2008-12-04 |
| AU2005245572B9 (en) | 2009-01-29 |
| CA2564654A1 (en) | 2005-12-01 |
| JP2007536920A (ja) | 2007-12-20 |
| EP1756306A2 (en) | 2007-02-28 |
| MXPA06013079A (es) | 2007-10-08 |
| US20080199855A1 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518307A2 (pt) | mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 | |
| Pfeffer et al. | A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands | |
| Loeffler-Ragg et al. | Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma | |
| Gualtieri et al. | Gene expression profiling of A549 cells exposed to Milan PM2. 5 | |
| Brustugun et al. | BRAF-mutations in non-small cell lung cancer | |
| Sun et al. | Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors | |
| Sikora et al. | Impact of cellular senescence signature on ageing research | |
| Dave et al. | Treatment resistance in stem cells and breast cancer | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| Lou et al. | Selective anticancer activity of hirsutine against HER2-positive breast cancer cells by inducing DNA damage | |
| ATE530635T1 (de) | Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status | |
| DK1926996T3 (da) | Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere | |
| WO2008127718A3 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
| JP2014074724A5 (enExample) | ||
| NO20074817L (no) | Epidermal vekstfaktorreseptor genkopiantall | |
| CA2699702A1 (en) | Cancer marker and therapeutic target | |
| BRPI0819018A2 (pt) | "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf" | |
| Feng et al. | High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non–small-cell lung Cancer | |
| Kang et al. | Histone H3 K4/9/27 trimethylation levels affect wound healing and stem cell dynamics in adult skin | |
| BR112021016595A2 (pt) | Método de diagnóstico ou prognóstico de câncer, métodos para diagnosticar câncer ou para triagem de câncer, para monitorar um indivíduo, para monitorar o tratamento de câncer, para avaliar a resposta de um indivíduo a um tratamento de câncer e para tratar um indivíduo com câncer detectado, kit e uso do kit | |
| Oyarzún et al. | Increased levels of adenosine and ecto 5′-nucleotidase (CD73) activity precede renal alterations in experimental diabetic rats | |
| Nausch et al. | NS19504: a novel BK channel activator with relaxing effect on bladder smooth muscle spontaneous phasic contractions | |
| Xu et al. | Atrophic dermatofibrosarcoma protuberans: a clinicopathological study of 16 cases | |
| Alrabadi et al. | Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma | |
| BRPI0511088A (pt) | identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |